{"id":"atimos","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Dry mouth"},{"rate":"1-3","effect":"Tremor"},{"rate":"2-5","effect":"Headache"},{"rate":"2-4","effect":"Pharyngitis"},{"rate":"1-2","effect":"Urinary retention"}]},"_chembl":{"chemblId":"CHEMBL1256786","moleculeType":"Small molecule","molecularWeight":"344.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tiotropium blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction. This produces sustained bronchodilation and improves lung function. The once-daily inhalation formulation provides 24-hour coverage for maintenance therapy in COPD.","oneSentence":"Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:24.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT01803087","phase":"PHASE2","title":"Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-02","conditions":"Asthma","enrollment":60},{"nctId":"NCT01946620","phase":"PHASE3","title":"A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD","status":"COMPLETED","sponsor":"Mundipharma Research Limited","startDate":"2013-10","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1767},{"nctId":"NCT01344655","phase":"PHASE4","title":"Study to Investigate the Effect of Formoterol vs Salmeterol on Small Airways Physiological Parameters in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01584492","phase":"PHASE2","title":"Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-12","conditions":"Asthma","enrollment":59}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atimos®","genericName":"Atimos®","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atimos is a tiotropium bromide inhalation powder that acts as a long-acting anticholinergic (muscarinic antagonist) to relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}